{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:02:35Z","timestamp":1793318555237,"version":"4.5.0"},"reference-count":21,"publisher":"Cambridge University Press (CUP)","issue":"12","license":[{"start":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T00:00:00Z","timestamp":1272585600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Large-scale population-based studies have reported a significant increase in invasive pneumococcal disease (IPD) in those with underlying haematological or solid-organ malignancy, but limited condition-specific data are available on rates of IPD in the adult population. A retrospective chart review of all patients with IPD (identified prospectively) in the province of Alberta, Canada (population ~3\u00b73 million) was conducted from 2000 to 2004 to study the epidemiology of IPD. Rates of IPD in patients with various haematological and solid-organ malignancies were determined by obtaining the number of these patients at risk from the provincial cancer registry. Compared to the attack rate of IPD in the adult population aged \u2a7e18 years (11\u00b70 cases\/100 000 per year, 95% CI 10\u00b744\u201311\u00b765), there were significantly increased rates of IPD in those with lung cancer (143\u00b76 cases\/100 000 per year, OR 13\u00b74, 95% CI 9\u00b73\u201319\u00b74, <jats:italic>P<\/jats:italic>&lt;0\u00b7001) and multiple myeloma (673\u00b79 cases\/100 000 per year, OR 62\u00b78, 95% CI 39\u00b76\u201399\u00b78, <jats:italic>P<\/jats:italic>&lt;0\u00b7001). More modestly increased rates of IPD were found in those with chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphoblastic leukaemia, and Hodgkin's and non-Hodgkin's lymphoma. There was an increased prevalence of serotype 6A in those with these underlying malignancies, but no other serotypes predominated. Fifty-three percent (48\/83) of cases were caused by serotypes in the investigational 13-valent pneumococcal conjugate vaccine (PCV13), and 57\/83 (69%) of the cases were caused by serotypes in the 23-valent pneumococcal polysaccharide vaccine (PPV23). The incidence of IPD in adults with certain haematological and solid-organ malignancies is significantly greater than the overall adult population. Such patients should be routinely given pneumococcal polysaccharide vaccine; this population could also be targeted for an expanded valency conjugate vaccine.<\/jats:p>","DOI":"10.1017\/s0950268810000919","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T11:47:51Z","timestamp":1272628071000},"page":"1804-1810","source":"Crossref","is-referenced-by-count":82,"title":["Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies"],"prefix":"10.1017","volume":"138","author":[{"given":"A.","family":"WONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"MARRIE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"GARG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"KELLNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"TYRRELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SPAT Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2010,4,30]]},"reference":[{"key":"S0950268810000919_ref010","doi-asserted-by":"publisher","DOI":"10.1086\/379016"},{"key":"S0950268810000919_ref019","first-page":"282","article-title":"Immunosuppression and infection in multiple myeloma","volume":"13","author":"Jacobson","year":"1986","journal-title":"Seminars in Oncology"},{"key":"S0950268810000919_ref002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710023371404"},{"key":"S0950268810000919_ref011","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1510"},{"key":"S0950268810000919_ref018","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb01601.x"},{"key":"S0950268810000919_ref014","unstructured":"14. Wang M .Surveillance analyst, Alberta Cancer Board, personal communication, 21 February 2008."},{"key":"S0950268810000919_ref017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06601.x"},{"key":"S0950268810000919_ref015","first-page":"238","volume-title":"Manual of Clinical Microbiology","author":"Facklam","year":"1991"},{"key":"S0950268810000919_ref003","first-page":"1","article-title":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"46","year":"1997","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268810000919_ref005","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000422.pub2"},{"key":"S0950268810000919_ref001","doi-asserted-by":"publisher","DOI":"10.1086\/377534"},{"key":"S0950268810000919_ref006","first-page":"1","article-title":"Recommended adult immunization schedules \u2013 United States, 2008","volume":"56","year":"2007","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268810000919_ref016","first-page":"241","volume-title":"Methods in Microbiology","volume":"12","author":"Lund","year":"1978"},{"key":"S0950268810000919_ref007","first-page":"267","volume-title":"Canadian Immunization Guide","year":"2006"},{"key":"S0950268810000919_ref020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1989.tb01119.x"},{"key":"S0950268810000919_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2006.06.007"},{"key":"S0950268810000919_ref009","doi-asserted-by":"publisher","DOI":"10.1086\/431521"},{"key":"S0950268810000919_ref021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068038"},{"key":"S0950268810000919_ref004","doi-asserted-by":"publisher","DOI":"10.1086\/319218"},{"key":"S0950268810000919_ref013","first-page":"S3","article-title":"Case definitions for diseases under national surveillance","volume":"26","year":"2000","journal-title":"Canadian Communicable Disease Report"},{"key":"S0950268810000919_ref012","unstructured":"12. Alberta Health and Wellness (AH&W).Population Projections for Alberta and its Health Regions, 2000\u20132030. Edmonton: AH&W, 2001."}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268810000919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T20:35:21Z","timestamp":1556397321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268810000919\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,30]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0950268810000919"],"URL":"https:\/\/doi.org\/10.1017\/s0950268810000919","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,30]]}}}